FindTrial
Sign In

Clinical Feasibility of Blood Biomarkers for Early and Differential Diagnosis of Alzheimer’s Disease in a Retrospective Cohort

Clinical Feasibility of Blood Biomarkers for Early and Differential Diagnosis of Alzheimer’s Disease in a Retrospective Cohort

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100597
Enrollment
Unknown
Registered
2025-04-11
Start date
2025-04-21
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective cognitive decline

Interventions

Gold Standard:Alzheimers disease was diagnosed based on the 2011/2018 NIA-AA dementia criteria and the International Working Group 2 guidelines.
Index test:GFAP, pTau-217, NfL, Aß1-42 and APOE e4

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Participants ranged from 30 to 90 years, with comprehensive clinical and neuropsychological assessments available in the biobank; 2.Diagnoses were made according to internationally recognized criteria.

Exclusion criteria

Exclusion criteria: 1.Exclusions included CNS infections, head trauma, other major neurological diseases, primary psychiatric disorders, and severe systemic conditions (e.g., malignancies).

Design outcomes

Primary

MeasureTime frame
Plasma GFAP levels;Plasma NfL levels;Plasma pTau-217 levels;Plasma APOE e4 levels;Plasma Aß1-42 levels;—

Secondary

MeasureTime frame
Biobank data;—

Countries

China

Contacts

Public ContactJintai Yu

Huashan Hospital, Fudan University

jintai_yu@fudan.edu.cn+86 18678999982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026